Bruno Pirovino-Zürcher
Executive Director Finance / Board Member
Erfahrungen
Executive Director Finance / Board Member
MITRELLI Group
Large scale tech infrastructure projects in EMEA
Director, Swiss Branch
DalCor Pharmaceuticals
Establish and manage a clinical trial in 32 countries. Foster close relationships with venture capitalists and board members - Rounds of financing (Series A, B, and C). Steer efforts in procurement, information technology, and compliance. Manage legal/contractual matters, as well as risk management, including insurance programs.
-
Set up Swiss operations & managed clinical trials (Phase II + III), performed several financing rounds (series A, B and C – total of 290M$), preparing the company for its exit, align due diligence processes, etc. by serving as global sponsor of phase II and III Clinical Trials in Precision medicine.
-
Developed and led business, drug supply and finance processes, incl. stakeholder management, people development, interaction with investors, management reporting, quarterly forecasting, budgeting, strategic long-range planning.
Business Services Director
Johnson & Johnson (CILAG INTERNATIONAL)
Delivered exceptional support with the integration of new J&J enterprises at the Zug headquarters. Establish and enhance business procedures and the exchange of best practices. Achieved desired goals by developing and leading cross-functional/cross-divisional projects, post-M&A integrations. Create, lead and implemented corporate programs such as Risk Management and Business Continuity Planning, Compliance, Data Privacy, Corporate Social Responsibility (CSR), Environment Health and Safety (EH&S) and Diversity&Inclusion.
-
Attained targeted goals by integrating Consumer Health, Pharma- and Medtech-business leading to synergies with double-digit savings.
-
Introduced Johnson & Johnson in Swiss Networks & Governments (e.g. American-Swiss Chamber of Commerce, Economic Promotion, Tax authorities).
Managing Director / Finance Director
EISAI PHARMA AG
Established Swiss commercial affiliate of a leading Japanese pharmaceutical company. Lead & develop strong business organisation, including Finance / Reporting / MIS / Performance Management, internal and external Audits & tax representation vis-à-vis Swiss tax authorities, Supply Chain/Risk management, Local Compliance Officer/Data Privacy, legal/contract management and strategic/mid-/short-term planning for existing and launch products. Drove pan-European collaboration within Eisai-group (focus: D-A-CH region). Served as business partner for local BD initiatives such as in-licensing, partnering, and launches). Foster collaboration between office- and field-based staff (e.g. joint calls). Rendered expertise in talent development, corporate social responsibility programs, and change and sales force effectiveness programs.
-
Successfully acquired and developed strategic product portfolio.
-
Effectively sustainable turnaround within nine months due to double-digit sales growth and cost-containments.
-
Incorporated as the No. 1 affiliate in the European corporate compliance program.
-
Stellar launch of new oncology franchise, best throughout Eisai Group in Europe
Owner / Managing Director & Interim Manager
FINCONOR gmbh
-
Board member, Interim CFO, strategic advisor to mature and ScaleUp organisations – managing international expansions in Europe and Africa. Driving excellence programs as Executive Director with focus on optimizing finance processes.
-
Senior leadership roles in turnaround and restructuring situations; Expert at Innosuisse
-
Drove Interim-management in senior financial positions (CFO/Finance Director/Group Controller) as well as finance and supply chain project management. Established and optimised procurement efforts - In/Out-Licensing in the pharmaceutical industry (RX/OTC).
-
Steered efforts in numerous projects in finance and real estate as well as strategy development in supply chain. Built group international controlling in a publicly-traded corporation incl. M&A activities. Integrated group-wide financial planning and reporting software (Hyperion). Ensured compliance with Swiss stock-exchange regulations/security regulatory agencies.
-
Business development in LifeScience / Healthcare
Financial Controller
BAKELS South Africa (PTY) LTD
2-years' project
COLT INTERNATIONAL (SCHWEIZ) AG
Finance roles with increasing responsibilities
Finance Manager (Switzerland)
IMS Information Medical Statistics AG
Project Manager (International)
IMS-HEALTH GROUP
PERKIN-ELMER
Finance roles with increasing responsibilities
Head of Finance/Accounting Central Eastern Europe (CEE)
PLIVA INTERNATIONAL AG
Zusammenfassung
Sprachen
Ausbildung
Swiss Board Institute - Universität St. Gallen / Université de Lausanne
Certified Director of the Board · International Board Certificate Program
The globalization of business means that international companies must navigate, control, and manage more complex competitive challenges, as well as learn how to govern and work across a variety of countries and cultures. Board members keep the big picture and values of the organization in mind and have the ability to act in complex markets and make decisions that contribute to the sustainable success of the organization. So what international companies and organizations need are board members who combine multicultural know-how with strategic leadership and governance skills in a humane and entrepreneurial way. The International Board Certificate Program (BoD CAS) aims to develop these board skills.